Historically speaking, Adeno-associated virus (AAV) is not a well-known virus. Its non-pathogenicity resulted in little to no attention given to it by the medical field in general. However as gene therapy gets more and more attention these days, scientists and researchers are scrambling to find the best possible viral vectors for human gene therapy applications. One of the most commonly used viruses nowadays in gene therapy is AAV.
AAV is valued by the gene therapy industry due to several factors. Firstly, its non-pathogenicity means that there is little to no chance of developing diseases on the patient after reintroduction into the body. This characteristic is important as several other viruses have been shown to cause cancer. Secondly, AAV has a wide array of available serotypes, 12 human serotypes and more than 100 animal serotypes, making it flexible for various applications.
As of date, 38 protocols involving AAV have been approved by the Recombinant DNA Advisory Committee and the Food and Drug Administration (FDA) for human clinical trials.
With these ongoing vector developments, continued effort has been focused on scalable manufacturing processes that can efficiently generate high-titer, highly pure, and potent quantities of rAAV vectors. Utilizing the relatively simple and efficient transfection system of HEK 293 T cells as a starting point.
Esco VacciXcell Advantage
Esco VacciXcell offers a wide range of bioreactors and fermenters that can produce recombinant DNA, recombinant viruses, miRNA adenoviruses, full-length ORF adenoviruses from different cell lines of mammalian cells, insect cells, etc.
Esco Vaccixcell tidemotion bioreactors, CelCradle™ and TideXcell™ are proven systems in culturing adherent cells such as HEK293. Our patented tidemotion technology along with proprietary BioNOC™ II macrocarriers ensures that the cells attach and stays attach during inoculation and culture process. The gentle tidemotion provides unlimited oxygenation and nutrion while virtually eliminating shear stress. Being the only TRUE LINEARLY SCALABLE system, from 0.5 L to 5,000 L, in the market, Esco Vaccixcell's tidemotion bioreactor reduces cost, labor requirement and bioprocessing time.
Esco VacciXcell's Tide Motion System is the highest yield and lowest cost packed bed bioreactor system and the only packed bed bioreactor that can be placed inside a cGMP isolator, making it an ideal system for the production of wild-type viruses.
On top of this, Esco VacciXcell can provide turnkey solutions for the gene therapy industry, beginning from research and development, all the way to the production scale of the end product.
Daya, S., & Berns, K. I. (2008). Gene therapy using adeno-associated virus vectors. Clinical microbiology reviews, 21(4), 583-593.
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., ... & Couto, L. B. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 101(8), 2963-2972.
Somia, N., & Verma, I. M. (2000). Gene therapy: trials and tribulations. Nature Reviews Genetics, 1(2), 91-99.
Zaiss, A. K., Liu, Q., Bowen, G. P., Wong, N. C., Bartlett, J. S., & Muruve, D. A. (2002). Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. Journal of virology, 76(9), 4580-4590.